SitemapContact Us
닫기
Search
Advanced Search +
닫기
Quick links
Most Cited Most Read Ahead of Print Archives Go to E-submission

Original Article

Split Viewer

Korean J Hematol 2010; 45(3):

Published online September 30, 2010

https://doi.org/10.5045/kjh.2010.45.3.158

© The Korean Society of Hematology

Induction of hypoxia-inducible factor-1α inhibits drug-induced apoptosis in the human leukemic cell line HL-60

Yeon-Joo Yook1, Young-Jin Seo1,2, Hyoung Jin Kang1, Sang-Hyeok Ko1, Hee Young Shin1, Jeong Jin Lee3, Gajin Jeong2, and Hyo Seop Ahn1*

Author Info. +

1Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

2Laboratory of Immunology, School of Biological Science, Seoul National University, Seoul, Korea.

3BioResearch Institute, Daewoong Pharmaceutical Co., Ltd., Seoul, Korea.

Correspondence to : Correspondence to Hyo Seop Ahn, M.D., Ph.D. Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-799, Korea. Tel: +82-2-2072-3625, Fax: +82-2-743-3455, hsahn@snu.ac.kr

Received: February 28, 2010; Revised: August 9, 2010; Accepted: September 2, 2010

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Go to

Background

Leukemic cells originate from hypoxic bone marrow, which protects them from anti-cancer drugs. Although many factors that cause drug resistance in leukemic cells have been studied, the effect of hypoxia on drug-induced apoptosis is still poorly understood.

Methods

In this study, we examined the effect of hypoxia on anti-leukemic drug resistance in leukemic cell lines treated with cobalt chloride (CoCl2), a hypoxia-mimetic agent. Cellular proliferation was evaluated using the methyl thiazolyl tetrazolium (MTT) assay. Flow cytometry analysis and western blots were performed to investigate apoptosis-related proteins.

Results

Unlike its previously known apoptotic effect, the expression of HIF-1α increased the survival rate of human promyelocytic leukemia HL-60 cells when these cells were exposed to anti-leukemic drugs; these effects were mediated by heat-shock protein HSP70 and the pro-apoptotic protein Bax.

Conclusion

These findings may provide new insights for understanding the mechanisms underlying hypoxia and for designing new therapeutic strategies for acute myeloid leukemia.

Keywords Hypoxia, Arsenic trioxide, HIF-1α, Cobalt chloride, Bax, HSP70

INTRODUCTION

Go to

Arsenic trioxide (ATO, As2O3) is a traditional Chinese medicine that has been used to treat several diseases such as anemia, dyspepsia, and some tumors [1]. ATO promotes elimination of acute promyelocytic leukemia (APL) by the induction of apoptosis [2]. The apoptotic effect of ATO is not restricted to APL but is also observed in other malignant cells including those of non-APL acute myeloid leukemia, myeloma, chronic myeloid leukemia, esophageal and ovarian carcinomas, and neuroblastoma [3-5].

Hypoxia or low oxygen tension is present at inflammatory sites, solid tumors, and bone marrow. To adapt to hypoxia, cells express many types of genes that are related to angiogenesis, mobility, and glucose metabolism through the hypoxia-inducible factor-1α (HIF-1α) [6-8]. HIF-1α is degraded by ubiquitination in the proteosome under conditions of normal oxygen tension (normoxia) even though it is constantly expressed. However, under hypoxia, HIF-1α is stabilized because of the lack of oxygen, and bound to constitutively expressed HIF-1β (ARNT). The HIF-1α/β heterodimer is bound to DNA at a specific recognition site known as the hypoxia response element (HRE), which initiates transcription of target genes [9, 10]. HIF-1α can be also stabilized by iron chelators and metal ions such as Co2+, Ni2+, and Mn2+ even under normoxia. In this study, we used cobalt chloride (CoCl2), a well-established chemical inducer of HIF-1α, to induce hypoxia-like responses [11].

Leukemic cells originate from bone marrow, which acts as a physical barrier to anticancer drugs. In addition, the microenvironment of bone marrow transmits survival signals that mediate adhesion through integrins and CD44 to fibronectin and hyaluronan [12, 13]. Although these factors increase leukemic cell resistance in the bone marrow to chemotherapeutic drugs, the survival effect of hypoxic bone marrow microenvironment on leukemic cells is still not understood.

Many previous studies have primarily focused on the apoptotic effect of hypoxia that affects cell survival and differentiation [14, 15]. The anti-apoptotic effect of hypoxia on several cell types has also been assessed [16-18]. Here, we investigated the relationship between hypoxia (using a mimetic agent) and drug resistance in leukemic cells to elucidate the contribution of hypoxic bone marrow microenvironment to failure of chemotherapeutic treatment.

MATERIALS AND METHODS

Go to
1. Cell culture and reagents

Four human leukemic cell lines (HL-60, APL; U937, acute myeloid leukemia; CCRF-CEM, acute lymphoblastic leukemia; K562, chronic myelogenous leukemia) were purchased from the Korean Cell Line Bank (KCLB; Seoul, Korea). All cells were cultured in RPMI-1640 (Invitrogen, Carlsbad, CA) supplemented with 10% FBS (Hyclone Laboratories, Inc., Logan, UT) and penicillin-streptomycin (Invitrogen). To induce expression of HIF-1α, cells were cultured with a cobalt chloride (CoCl2; Sigma, St. Louis, MO).

2. Cell proliferation assay: MTT assay

The cell proliferation rate was determined by measuring the absorbance of the MTT dye (3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide; Sigma) in living cells. Cells were inoculated in each well of a 12- or 24-well tissue culture plate. After 3 d, the MTT solution was added to each well and the plates were incubated for 3 or 4 hr at 37℃. Supernatants were then removed, and 100 µL of 0.04 N HCl-isopropanol was added to solubilize the formazan crystal formed by succinate dehydrogenase activity in viable cells. The plates were shaken at room temperature for 30 min, and then the absorbance at 540 nm was measured on a ThermoMAX microplate reader (Molecular Devices, Sunnyvale, CA).

3. Detection of apoptosis

Apoptotic cell death was detected by an annexin V-FITC/PI apoptosis detection kit (BD Pharmingen, San Diego, CA) or a caspase-3 detection kit (BD Pharmingen) according to the manufacturer's instructions. For the annexin V-FITC/PI kit, after adding 5 µL annexin V-FITC and 5 µL propidium iodide (PI), cells were incubated for 15 min at room temperature in the dark. Flow cytometry analysis was carried out within 1 hr. For caspase-3 detection, cells were washed twice with cold PBS and then resuspended in a Cytofix/Cytoperm solution and incubated for 20 min on ice. Following washing with a Perm/Wash buffer, cells were resuspended in a Perm/Wash buffer containing an anti-active caspase-3 antibody and incubated for 30 min at room temperature. After washing with a Perm/Wash buffer, the cells were prepared for flow cytometry analysis.

4. Western blot analysis

Total proteins were extracted by Pro-Prep (InTron Inc., Seoul, Korea) supplemented with phosphatase inhibitors (Sigma) and then normalized with a Micro BCA reagent (Pierce, Rockford, IL). Protein samples (30 µg each) were run on a 10% SDS-PAGE gel and transferred to PROTRAN-NC (Whatman, Clifton, NJ). Blots were blocked with 5% skim milk in TBST (0.1% Tween 20 in Tris-Buffered Saline) at room temperature for 1 hr and then incubated with Bax, HSP70, HSP90, Bcl-2, ERK, phospho-ERK, p38, phospho-p38, α-tubulin (Cell Signaling Technology Inc., Danvers, MA), or HIF-1α (BD Pharmingen) antibodies in blocking buffer (1:1,000) at 4℃ overnight. After washing 3 times with TBST, blots were incubated with horseradish-peroxidase (HRP)-conjugated secondary antibodies in blocking buffer (1:5,000) at room temperature for 1 hr. Blots were then washed 5 times with TBST and developed with the Super-signal reagent (Pierce).

5. HIF-1α inhibition assay

HL-60 cells were pre-treated with cadmium chloride (20 µM, CdCl2; Sigma) for 12 hr then cultured for 48 hr with CoCl2. Cell viability was assessed by the MTT assay, and HIF-1α expression was checked by western blot analysis as described above. The experiments were repeated 3 separate times under each set of conditions.

6. Statistical analysis

Data were expressed as the mean±SEM (standard error of the mean) of 3 experiments and were analyzed with an unpaired two-tailed Student's t-test. Significance was established when P<0.05.

RESULTS

Go to
1. CoCl<sub>2</sub> increases resistance of HL-60 cells to actinomycin-D

Leukemia cells originating from the bone marrow are under hypoxic conditions, which is in contrast to normoxic peripheral blood. We first investigated whether hypoxia-like conditions increased resistance of leukemic cells to actinomycin-D (Act-D)-induced oxidative stress-dependent apoptosis in U937, HL-60, CCRF-CEM, and K562 cells [19]. Among the 4 different leukemic cell lines, HL-60 cells were resistant to Act-D-induced cell death by treatment with CoCl2 (PI negative population: Act-D-treated, 5.8% vs. Act-D/CoCl2-treated, 47.09%) (Fig. 1). The protective effect of CoCl2 was significantly increased at higher doses of Act-D (0.125 and 1.0 µg/mL). These results indicate that CoCl2 increases resistance of HL-60 cells to Act-D-induced cell death.

2. CoCl<sub>2</sub> increases resistance of HL-60 cells to anti-leukemic drugs

Next, we tested the resistance of leukemic cells to several anti-leukemic drugs that are used for leukemia treatment because development of drug resistance is the most important factor associated with the failure of leukemic cell chemotherapeutic treatments. Each cell line was treated with an anti-leukemic drug: ATO (A), 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), an HSP90 inhibitor (B), valproic acid (C), and cytarabine (D), in the presence or absence of CoCl2 (Fig. 2). Among the 4 cell lines, HL-60 cells were resistant under CoCl2-treatment conditions to each of the above anti-leukemic drugs (ATO, 1.41-fold increase, P=0.009; 17-AAG, 1.54-fold increase, P=0.002; valproic acid, 1.19-fold increase, P=0.007; cytarabine, 1.18-fold increase, P=0.053). K562 was resistant to only 17-AAG. In contrast, the treatment of CCRF-CEM cells with CoCl2 strongly decreased cell viability in the presence and absence of the anti-leukemic drugs (Fig. 1A and Fig. 2).

3. CoCl<sub>2</sub> prevents apoptotic cell death in HL-60 cells via regulation of the apoptotic pathway

To verify whether hypoxia-like conditions inhibit HL-60 cell death by blocking the apoptotic pathway, we investigated the expression level of several apoptosis-related genes by western blot analysis based on previous results in 4 cell lines. Intriguingly, CoCl2 affects the expression of both the pro-apoptotic protein Bax (down-regulation) and the heat shock protein HSP70 (up-regulation), which are the main regulators of ATO-induced cell death [20, 21], but did not affect the expression of Bcl-2 or HSP90 (Fig. 3A, B). Moreover, we found that CoCl2 increased the phosphorylation levels of survival-related ERK and p38 (Fig. 3B). However, in K562 cells (Fig. 3A), U937, and CCRF-CEM cells (data not shown), there was no significant difference in the expression of Bax and HSP70 between CoCl2-treated and -untreated conditions. In addition, the level of cleaved caspase-3 was decreased with CoCl2 treatment in the presence of ATO, as compared to ATO in the absence of CoCl2 (Fig. 3C, mean fluorescence intensity (MFI); 152 vs. 213). Similarly, annexin V-FITC/PI analysis indicated that CoCl2 treatment decreased the apoptotic population of ATO-treated cells (Fig. 3D, annexin V/PI double positive: 25% vs. 15%). Collectively, these results demonstrate that CoCl2 treatment prevents apoptosis of ATO-treated HL-60 cells through the regulation of HSP70 and Bax.

4. HIF-1α induction by CoCl<sub>2</sub> increases the survival rate of HL-60 cells

As shown in Fig. 4, CoCl2 strongly increased the expression level of HIF-1α in a CoCl2-dose dependent manner (Fig. 4A) without significant cell death (data not shown). To determine if the effect of CoCl2 on decreased apoptosis was mediated by HIF-1α, we performed an inhibition assay using CdCl2, an inhibitor of HIF-1α activation [22]. CdCl2 effectively decreased the expression level of HIF-1α (Fig. 4B). While resistance of HL-60 cells was significantly increased more than 2-fold by CoCl2, treatment with CdCl2 reduced the survival rate of ATO-treated cells. These results show that the induction of HIF-1α by CoCl2 increases resistance of HL-60 cells to ATO.

DISCUSSION

Go to

Under hypoxia, the expression of migration and angiogenesis-related genes can be an important survival strategy in solid cancer cells. In contrast, some cells like immune cells in inflammatory sites and hematopoietic progenitor cells in bone marrow stay in hypoxic sites. In particular, the bone marrow provides both a physical barrier and survival signals to resident leukemic cells [12, 13]. Therefore, its protective effect increases resistance to anti-leukemic drugs. However, the effect of the hypoxic bone marrow micro-environment on leukemic cell survival is still unknown, although we previously reported that hypoxia decreases the migration rate of leukemia cells [23]. In this study, we examined the relationship between leukemic cell survival and HIF-1α, which is an essential effector of hypoxia.

First, we determined that CoCl2 treatment dramatically increased resistance of HL-60 cells to Act-D, an inducer of apoptosis, in a dose-dependent manner. Although the survival rate of HL-60 cells was not high due to the potent effect of Act-D, CoCl2 treatment strongly increased the PI negative population more than 7-fold. We then examined the effect of CoCl2 on cells treated with anti-leukemic drugs. CoCl2 increased resistance of HL-60 cells to ATO, 17-AAG, valproic acid, and cytarabine. However, we did not observe a protective effect of CoCl2 on other leukemia cell lines. For example, CCRF-CEM cells were relatively sensitive to CoCl2 treatment. These observations indicate that the anti-apoptotic effect of CoCl2 depends on the specific leukemic cell type.

ATO is currently used for acute promyeloid leukemia therapy due to its potential as an inducer of cell death through regulation of apoptosis-related molecules [2]. Results from the annexin V/PI analysis and caspase-3 activation assay indicated that CoCl2 treatment reversed the ATO-induced apoptotic rate of acute promyelocytic HL-60 cells. Although it is known that ATO induces cell death through the regulation of HSP70, HSP90, Bax, and Bcl-2 molecules [20, 21], our results indicate that CoCl2 regulates only HSP70 and Bax in ATO-treated HL-60 cells. Because the HSP70/Bax axis plays a critical role in the intrinsic apoptotic pathway [24, 25], its regulation by CoCl2 can be a potential mechanism to explain our observations. CoCl2 treatment also results in the phosphorylation and therefore activation of ERK and p38, which are related to increased survival of leukemic cells [26]. Data from the HIF-1α inhibition assay indicates that the survival effects of CoCl2 on ATO-treated HL-60 cells are strongly correlated with the expression of HIF-1α.

In some patients with leukemia, after initial chemotherapy, a small number of leukemic cells survive, develop resistance to treatment, and the disease returns. The most common relapse site of leukemia is the bone marrow where the leukemia originated. In addition to survival benefits provided by the bone marrow because of transmission of several survival factors to leukemic cells, such as cytokines and adhesion molecules [12, 13, 27], our results indicate that the hypoxic microenvironment of bone marrow may be a critical survival factor for leukemic cells. These discoveries provide new insights for understanding the mechanisms underlying hypoxia and for designing new therapeutic strategies for acute myeloid leukemia.

FIGURES

Go to
Fig. 1.

CoCl2 increases the resistance of HL-60 to Actinomycin-D (Act-D). (A) HL-60, U937, K562, and CCRF-CEM cells were cultured for 8 hrs with or without CoCl2 (100 µM) and for additional 15 hrs in the presence of Act-D (1 µg/mL). Cells were then analyzed for PI negative population by flow cytometry. CTR, control. (B) HL-60 cells were pre-treated with various doses of CoCl2 for 8 hrs and then cultured for 15 hrs with indicated doses of Act-D. Cell viability was evaluated by the MTT assay. The relative viable cell number was calculated as the ratio of each optical density (OD) to the control OD. Results are expressed as relative viability±SEM. An asterisk (*) represents statistical significance when the P-value is lower than 0.05.


Fig. 2.

CoCl2 increases the resistance of HL-60 to anti-leukemic drugs. HL-60, U937, K562, and CCRF-CEM cells were cultured for 15 hrs in the presence or absence of CoCl2. Cells were then cultured for another 15 hrs with or without (A) ATO (2.5 µM), (B) 17-AAG (1 µM), (C) valproic acid (5 mM), or (D) cytarabine (1 µM). Cell viability was analyzed by the MTT assay. The relative viable cell number was calculated as the ratio of each OD to the OD of cells treated with drug alone (set as 1.0). Results are expressed as relative viability±SEM. Asterisk (*) indicates statistical significance when the P-value is lower than 0.05.


Fig. 3.

CoCl2 decreases the apoptotic rate of HL-60 cells through the HSP70/Bax pathway. (A) HL-60 or K562 cells were cultured for 24 hrs in the presence or absence of CoCl2. Expression levels of HSP90, HSP70, and Bax were analyzed by western blotting. An α-tubulin antibody was used as an internal control. (B) HL-60 cells were cultured with indicated dose of CoCl2 for 24 hrs. The expression levels of Bax, Bcl-2, ERK, phospho-ERK, HSP70, HSP90, p38, and phospho-p38 were analyzed by western blotting. (C) HL-60 cells were cultured with or without CoCl2 in the presence of ATO for 24 hrs. The amount of cleaved caspase-3 was assessed by flow cytometry. (D) HL-60 cells were cultured with or without ATO in the presence or absence of CoCl2 for 24 hrs. Cells were stained with annexin V/PI and then analyzed by flow cytometry.


Fig. 4.

The expression of HIF-1α increases the resistance of HL-60 cells to ATO. (A) HL-60 cells were cultured in the presence of the indicated doses of CoCl2 for 24 hrs. Expression of HIF-1α was then analyzed by western blotting. A β-actin antibody was used as an internal control. (B) HL-60 cells were cultured in the presence or absence of CdCl2 and/or CoCl2 for 12 hrs and with ATO for additional 48 hrs. Cell viability was analyzed by the MTT assay. The relative viable cell number was calculated as the ratio of each OD to the control OD. Results are expressed as relative viability±SEM. Two asterisks (*) represents statistical significance when the P-value is lower than 0.01.


REFERENCES

Go to
  1. Zhang, TC, Cao, EH, Li, JF, Ma, W, Qin, JF. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer, 1999;35;1258-1263.
    Pubmed
  2. Park, JW, Choi, YJ, Jang, MA, et al. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun, 2001;286;726-734.
    Pubmed
  3. Uslu, R, Sanli, UA, Sezgin, C, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res, 2000;6;4957-4964.
    Pubmed
  4. Shen, ZY, Shen, J, Cai, WJ, Hong, C, Zheng, MH. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med, 2000;5;155-158.
    Pubmed
  5. Maeda, H, Hori, S, Nishitoh, H, et al. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res, 2001;61;5432-5440.
    Pubmed
  6. Semenza, GL. HIF-1 and human disease: one highly involved factor. Genes Dev, 2000;14;1983-1991.
    Pubmed
  7. Maxwell, PH, Dachs, GU, Gleadle, JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA, 1997;94;8104-8109.
    Pubmed
  8. Dachs, GU, Patterson, AV, Firth, JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med, 1997;3;515-520.
    Pubmed
  9. Semenza, GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med, 2002;8;S62-S67.
    Pubmed
  10. Semenza, GL. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med, 2003;54;17-28.
    Pubmed
  11. Yuan, Y, Hilliard, G, Ferguson, T, Millhorn, DE. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem, 2003;278;15911-15916.
    Pubmed
  12. Jin, L, Hope, KJ, Zhai, Q, Smadja-Joffe, F, Dick, JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med, 2006;12;1167-1174.
    Pubmed
  13. Matsunaga, T, Takemoto, N, Sato, T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med, 2003;9;1158-1165.
    Pubmed
  14. Saitoh, Y, Ouchida, R, Miwa, N. Bcl-2 prevents hypoxia/reoxygenation-induced cell death through suppressed generation of reactive oxygen species and upregulation of Bcl-2 proteins. J Cell Biochem, 2003;90;914-924.
    Pubmed
  15. Santore, MT, McClintock, DS, Lee, VY, Budinger, GR, Chandel, NS. Anoxia-induced apoptosis occurs through a mitochondria-dependent pathway in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol, 2002;282;L727-L734.
    Pubmed
  16. Hussein, D, Estlin, EJ, Dive, C, Makin, GW. Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther, 2006;5;2241-2250.
    Pubmed
  17. Song, X, Liu, X, Chi, W, et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol, 2006;58;776-784.
    Pubmed
  18. Walmsley, SR, Print, C, Farahi, N, et al. Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med, 2005;201;105-115.
    Pubmed
  19. Li, Q, Sato, EF, Zhu, X, Inoue, M. A simultaneous release of SOD1 with cytochrome c regulates mitochondria-dependent apoptosis. Mol Cell Biochem, 2009;322;151-159.
    Pubmed
  20. Khalil, S, Luciano, J, Chen, W, Liu, AY. Dynamic regulation and involvement of the heat shock transcriptional response in arsenic carcinogenesis. J Cell Physiol, 2006;207;562-569.
    Pubmed
  21. Ramos, AM, Aller, P. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines. Biochem Pharmacol, 2008;75;1912-1923.
    Pubmed
  22. Chun, YS, Choi, E, Kim, GT, et al. Cadmium blocks hypoxia-inducible factor (HIF)-1-mediated response to hypoxia by stimulating the proteasome-dependent degradation of HIF-1alpha. Eur J Biochem, 2000;267;4198-4204.
    Pubmed
  23. Seo, YJ, Koh, SH, Kang, HJ, Shin, HY, Jeong, G, Ahn, HS. Hypoxia inhibits the SDF-1-dependent migration of human leukemic cell line HL-60 via blocking of Akt activation. Biochem Biophys Res Commun, 2007;364;388-394.
    Pubmed
  24. Nagata, S. Apoptotic DNA fragmentation. Exp Cell Res, 2000;256;12-18.
    Pubmed
  25. Takahashi, Y, Karbowski, M, Yamaguchi, H, et al. Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. Mol Cell Biol, 2005;25;9369-9382.
    Pubmed
  26. Platanias, LC. Map kinase signaling pathways and hematologic malignancies. Blood, 2003;101;4667-4679.
    Pubmed
  27. Bendall, LJ, Makrynikola, V, Hutchinson, A, Bianchi, AC, Bradstock, KF, Gottlieb, DJ. Stem cell factor enhances the adhesion of AML cells to fibronectin and augments fibronectin-mediated anti-apoptotic and proliferative signals. Leukemia, 1998;12;1375-1382.
    Pubmed

Article

Original Article

Korean J Hematol 2010; 45(3): 158-163

Published online September 30, 2010 https://doi.org/10.5045/kjh.2010.45.3.158

Copyright © The Korean Society of Hematology.

Induction of hypoxia-inducible factor-1α inhibits drug-induced apoptosis in the human leukemic cell line HL-60

Yeon-Joo Yook1, Young-Jin Seo1,2, Hyoung Jin Kang1, Sang-Hyeok Ko1, Hee Young Shin1, Jeong Jin Lee3, Gajin Jeong2, and Hyo Seop Ahn1*

1Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

2Laboratory of Immunology, School of Biological Science, Seoul National University, Seoul, Korea.

3BioResearch Institute, Daewoong Pharmaceutical Co., Ltd., Seoul, Korea.

Correspondence to: Correspondence to Hyo Seop Ahn, M.D., Ph.D. Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-799, Korea. Tel: +82-2-2072-3625, Fax: +82-2-743-3455, hsahn@snu.ac.kr

Received: February 28, 2010; Revised: August 9, 2010; Accepted: September 2, 2010

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Leukemic cells originate from hypoxic bone marrow, which protects them from anti-cancer drugs. Although many factors that cause drug resistance in leukemic cells have been studied, the effect of hypoxia on drug-induced apoptosis is still poorly understood.

Methods

In this study, we examined the effect of hypoxia on anti-leukemic drug resistance in leukemic cell lines treated with cobalt chloride (CoCl2), a hypoxia-mimetic agent. Cellular proliferation was evaluated using the methyl thiazolyl tetrazolium (MTT) assay. Flow cytometry analysis and western blots were performed to investigate apoptosis-related proteins.

Results

Unlike its previously known apoptotic effect, the expression of HIF-1α increased the survival rate of human promyelocytic leukemia HL-60 cells when these cells were exposed to anti-leukemic drugs; these effects were mediated by heat-shock protein HSP70 and the pro-apoptotic protein Bax.

Conclusion

These findings may provide new insights for understanding the mechanisms underlying hypoxia and for designing new therapeutic strategies for acute myeloid leukemia.

Keywords: Hypoxia, Arsenic trioxide, HIF-1α, Cobalt chloride, Bax, HSP70

INTRODUCTION

Arsenic trioxide (ATO, As2O3) is a traditional Chinese medicine that has been used to treat several diseases such as anemia, dyspepsia, and some tumors [1]. ATO promotes elimination of acute promyelocytic leukemia (APL) by the induction of apoptosis [2]. The apoptotic effect of ATO is not restricted to APL but is also observed in other malignant cells including those of non-APL acute myeloid leukemia, myeloma, chronic myeloid leukemia, esophageal and ovarian carcinomas, and neuroblastoma [3-5].

Hypoxia or low oxygen tension is present at inflammatory sites, solid tumors, and bone marrow. To adapt to hypoxia, cells express many types of genes that are related to angiogenesis, mobility, and glucose metabolism through the hypoxia-inducible factor-1α (HIF-1α) [6-8]. HIF-1α is degraded by ubiquitination in the proteosome under conditions of normal oxygen tension (normoxia) even though it is constantly expressed. However, under hypoxia, HIF-1α is stabilized because of the lack of oxygen, and bound to constitutively expressed HIF-1β (ARNT). The HIF-1α/β heterodimer is bound to DNA at a specific recognition site known as the hypoxia response element (HRE), which initiates transcription of target genes [9, 10]. HIF-1α can be also stabilized by iron chelators and metal ions such as Co2+, Ni2+, and Mn2+ even under normoxia. In this study, we used cobalt chloride (CoCl2), a well-established chemical inducer of HIF-1α, to induce hypoxia-like responses [11].

Leukemic cells originate from bone marrow, which acts as a physical barrier to anticancer drugs. In addition, the microenvironment of bone marrow transmits survival signals that mediate adhesion through integrins and CD44 to fibronectin and hyaluronan [12, 13]. Although these factors increase leukemic cell resistance in the bone marrow to chemotherapeutic drugs, the survival effect of hypoxic bone marrow microenvironment on leukemic cells is still not understood.

Many previous studies have primarily focused on the apoptotic effect of hypoxia that affects cell survival and differentiation [14, 15]. The anti-apoptotic effect of hypoxia on several cell types has also been assessed [16-18]. Here, we investigated the relationship between hypoxia (using a mimetic agent) and drug resistance in leukemic cells to elucidate the contribution of hypoxic bone marrow microenvironment to failure of chemotherapeutic treatment.

MATERIALS AND METHODS

1. Cell culture and reagents

Four human leukemic cell lines (HL-60, APL; U937, acute myeloid leukemia; CCRF-CEM, acute lymphoblastic leukemia; K562, chronic myelogenous leukemia) were purchased from the Korean Cell Line Bank (KCLB; Seoul, Korea). All cells were cultured in RPMI-1640 (Invitrogen, Carlsbad, CA) supplemented with 10% FBS (Hyclone Laboratories, Inc., Logan, UT) and penicillin-streptomycin (Invitrogen). To induce expression of HIF-1α, cells were cultured with a cobalt chloride (CoCl2; Sigma, St. Louis, MO).

2. Cell proliferation assay: MTT assay

The cell proliferation rate was determined by measuring the absorbance of the MTT dye (3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide; Sigma) in living cells. Cells were inoculated in each well of a 12- or 24-well tissue culture plate. After 3 d, the MTT solution was added to each well and the plates were incubated for 3 or 4 hr at 37℃. Supernatants were then removed, and 100 µL of 0.04 N HCl-isopropanol was added to solubilize the formazan crystal formed by succinate dehydrogenase activity in viable cells. The plates were shaken at room temperature for 30 min, and then the absorbance at 540 nm was measured on a ThermoMAX microplate reader (Molecular Devices, Sunnyvale, CA).

3. Detection of apoptosis

Apoptotic cell death was detected by an annexin V-FITC/PI apoptosis detection kit (BD Pharmingen, San Diego, CA) or a caspase-3 detection kit (BD Pharmingen) according to the manufacturer's instructions. For the annexin V-FITC/PI kit, after adding 5 µL annexin V-FITC and 5 µL propidium iodide (PI), cells were incubated for 15 min at room temperature in the dark. Flow cytometry analysis was carried out within 1 hr. For caspase-3 detection, cells were washed twice with cold PBS and then resuspended in a Cytofix/Cytoperm solution and incubated for 20 min on ice. Following washing with a Perm/Wash buffer, cells were resuspended in a Perm/Wash buffer containing an anti-active caspase-3 antibody and incubated for 30 min at room temperature. After washing with a Perm/Wash buffer, the cells were prepared for flow cytometry analysis.

4. Western blot analysis

Total proteins were extracted by Pro-Prep (InTron Inc., Seoul, Korea) supplemented with phosphatase inhibitors (Sigma) and then normalized with a Micro BCA reagent (Pierce, Rockford, IL). Protein samples (30 µg each) were run on a 10% SDS-PAGE gel and transferred to PROTRAN-NC (Whatman, Clifton, NJ). Blots were blocked with 5% skim milk in TBST (0.1% Tween 20 in Tris-Buffered Saline) at room temperature for 1 hr and then incubated with Bax, HSP70, HSP90, Bcl-2, ERK, phospho-ERK, p38, phospho-p38, α-tubulin (Cell Signaling Technology Inc., Danvers, MA), or HIF-1α (BD Pharmingen) antibodies in blocking buffer (1:1,000) at 4℃ overnight. After washing 3 times with TBST, blots were incubated with horseradish-peroxidase (HRP)-conjugated secondary antibodies in blocking buffer (1:5,000) at room temperature for 1 hr. Blots were then washed 5 times with TBST and developed with the Super-signal reagent (Pierce).

5. HIF-1α inhibition assay

HL-60 cells were pre-treated with cadmium chloride (20 µM, CdCl2; Sigma) for 12 hr then cultured for 48 hr with CoCl2. Cell viability was assessed by the MTT assay, and HIF-1α expression was checked by western blot analysis as described above. The experiments were repeated 3 separate times under each set of conditions.

6. Statistical analysis

Data were expressed as the mean±SEM (standard error of the mean) of 3 experiments and were analyzed with an unpaired two-tailed Student's t-test. Significance was established when P<0.05.

RESULTS

1. CoCl<sub>2</sub> increases resistance of HL-60 cells to actinomycin-D

Leukemia cells originating from the bone marrow are under hypoxic conditions, which is in contrast to normoxic peripheral blood. We first investigated whether hypoxia-like conditions increased resistance of leukemic cells to actinomycin-D (Act-D)-induced oxidative stress-dependent apoptosis in U937, HL-60, CCRF-CEM, and K562 cells [19]. Among the 4 different leukemic cell lines, HL-60 cells were resistant to Act-D-induced cell death by treatment with CoCl2 (PI negative population: Act-D-treated, 5.8% vs. Act-D/CoCl2-treated, 47.09%) (Fig. 1). The protective effect of CoCl2 was significantly increased at higher doses of Act-D (0.125 and 1.0 µg/mL). These results indicate that CoCl2 increases resistance of HL-60 cells to Act-D-induced cell death.

2. CoCl<sub>2</sub> increases resistance of HL-60 cells to anti-leukemic drugs

Next, we tested the resistance of leukemic cells to several anti-leukemic drugs that are used for leukemia treatment because development of drug resistance is the most important factor associated with the failure of leukemic cell chemotherapeutic treatments. Each cell line was treated with an anti-leukemic drug: ATO (A), 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), an HSP90 inhibitor (B), valproic acid (C), and cytarabine (D), in the presence or absence of CoCl2 (Fig. 2). Among the 4 cell lines, HL-60 cells were resistant under CoCl2-treatment conditions to each of the above anti-leukemic drugs (ATO, 1.41-fold increase, P=0.009; 17-AAG, 1.54-fold increase, P=0.002; valproic acid, 1.19-fold increase, P=0.007; cytarabine, 1.18-fold increase, P=0.053). K562 was resistant to only 17-AAG. In contrast, the treatment of CCRF-CEM cells with CoCl2 strongly decreased cell viability in the presence and absence of the anti-leukemic drugs (Fig. 1A and Fig. 2).

3. CoCl<sub>2</sub> prevents apoptotic cell death in HL-60 cells via regulation of the apoptotic pathway

To verify whether hypoxia-like conditions inhibit HL-60 cell death by blocking the apoptotic pathway, we investigated the expression level of several apoptosis-related genes by western blot analysis based on previous results in 4 cell lines. Intriguingly, CoCl2 affects the expression of both the pro-apoptotic protein Bax (down-regulation) and the heat shock protein HSP70 (up-regulation), which are the main regulators of ATO-induced cell death [20, 21], but did not affect the expression of Bcl-2 or HSP90 (Fig. 3A, B). Moreover, we found that CoCl2 increased the phosphorylation levels of survival-related ERK and p38 (Fig. 3B). However, in K562 cells (Fig. 3A), U937, and CCRF-CEM cells (data not shown), there was no significant difference in the expression of Bax and HSP70 between CoCl2-treated and -untreated conditions. In addition, the level of cleaved caspase-3 was decreased with CoCl2 treatment in the presence of ATO, as compared to ATO in the absence of CoCl2 (Fig. 3C, mean fluorescence intensity (MFI); 152 vs. 213). Similarly, annexin V-FITC/PI analysis indicated that CoCl2 treatment decreased the apoptotic population of ATO-treated cells (Fig. 3D, annexin V/PI double positive: 25% vs. 15%). Collectively, these results demonstrate that CoCl2 treatment prevents apoptosis of ATO-treated HL-60 cells through the regulation of HSP70 and Bax.

4. HIF-1α induction by CoCl<sub>2</sub> increases the survival rate of HL-60 cells

As shown in Fig. 4, CoCl2 strongly increased the expression level of HIF-1α in a CoCl2-dose dependent manner (Fig. 4A) without significant cell death (data not shown). To determine if the effect of CoCl2 on decreased apoptosis was mediated by HIF-1α, we performed an inhibition assay using CdCl2, an inhibitor of HIF-1α activation [22]. CdCl2 effectively decreased the expression level of HIF-1α (Fig. 4B). While resistance of HL-60 cells was significantly increased more than 2-fold by CoCl2, treatment with CdCl2 reduced the survival rate of ATO-treated cells. These results show that the induction of HIF-1α by CoCl2 increases resistance of HL-60 cells to ATO.

DISCUSSION

Under hypoxia, the expression of migration and angiogenesis-related genes can be an important survival strategy in solid cancer cells. In contrast, some cells like immune cells in inflammatory sites and hematopoietic progenitor cells in bone marrow stay in hypoxic sites. In particular, the bone marrow provides both a physical barrier and survival signals to resident leukemic cells [12, 13]. Therefore, its protective effect increases resistance to anti-leukemic drugs. However, the effect of the hypoxic bone marrow micro-environment on leukemic cell survival is still unknown, although we previously reported that hypoxia decreases the migration rate of leukemia cells [23]. In this study, we examined the relationship between leukemic cell survival and HIF-1α, which is an essential effector of hypoxia.

First, we determined that CoCl2 treatment dramatically increased resistance of HL-60 cells to Act-D, an inducer of apoptosis, in a dose-dependent manner. Although the survival rate of HL-60 cells was not high due to the potent effect of Act-D, CoCl2 treatment strongly increased the PI negative population more than 7-fold. We then examined the effect of CoCl2 on cells treated with anti-leukemic drugs. CoCl2 increased resistance of HL-60 cells to ATO, 17-AAG, valproic acid, and cytarabine. However, we did not observe a protective effect of CoCl2 on other leukemia cell lines. For example, CCRF-CEM cells were relatively sensitive to CoCl2 treatment. These observations indicate that the anti-apoptotic effect of CoCl2 depends on the specific leukemic cell type.

ATO is currently used for acute promyeloid leukemia therapy due to its potential as an inducer of cell death through regulation of apoptosis-related molecules [2]. Results from the annexin V/PI analysis and caspase-3 activation assay indicated that CoCl2 treatment reversed the ATO-induced apoptotic rate of acute promyelocytic HL-60 cells. Although it is known that ATO induces cell death through the regulation of HSP70, HSP90, Bax, and Bcl-2 molecules [20, 21], our results indicate that CoCl2 regulates only HSP70 and Bax in ATO-treated HL-60 cells. Because the HSP70/Bax axis plays a critical role in the intrinsic apoptotic pathway [24, 25], its regulation by CoCl2 can be a potential mechanism to explain our observations. CoCl2 treatment also results in the phosphorylation and therefore activation of ERK and p38, which are related to increased survival of leukemic cells [26]. Data from the HIF-1α inhibition assay indicates that the survival effects of CoCl2 on ATO-treated HL-60 cells are strongly correlated with the expression of HIF-1α.

In some patients with leukemia, after initial chemotherapy, a small number of leukemic cells survive, develop resistance to treatment, and the disease returns. The most common relapse site of leukemia is the bone marrow where the leukemia originated. In addition to survival benefits provided by the bone marrow because of transmission of several survival factors to leukemic cells, such as cytokines and adhesion molecules [12, 13, 27], our results indicate that the hypoxic microenvironment of bone marrow may be a critical survival factor for leukemic cells. These discoveries provide new insights for understanding the mechanisms underlying hypoxia and for designing new therapeutic strategies for acute myeloid leukemia.

Fig 1.

Download
Figure 1.

CoCl2 increases the resistance of HL-60 to Actinomycin-D (Act-D). (A) HL-60, U937, K562, and CCRF-CEM cells were cultured for 8 hrs with or without CoCl2 (100 µM) and for additional 15 hrs in the presence of Act-D (1 µg/mL). Cells were then analyzed for PI negative population by flow cytometry. CTR, control. (B) HL-60 cells were pre-treated with various doses of CoCl2 for 8 hrs and then cultured for 15 hrs with indicated doses of Act-D. Cell viability was evaluated by the MTT assay. The relative viable cell number was calculated as the ratio of each optical density (OD) to the control OD. Results are expressed as relative viability±SEM. An asterisk (*) represents statistical significance when the P-value is lower than 0.05.

Blood Research 2010; 45: 158-163https://doi.org/10.5045/kjh.2010.45.3.158

Fig 2.

Download
Figure 2.

CoCl2 increases the resistance of HL-60 to anti-leukemic drugs. HL-60, U937, K562, and CCRF-CEM cells were cultured for 15 hrs in the presence or absence of CoCl2. Cells were then cultured for another 15 hrs with or without (A) ATO (2.5 µM), (B) 17-AAG (1 µM), (C) valproic acid (5 mM), or (D) cytarabine (1 µM). Cell viability was analyzed by the MTT assay. The relative viable cell number was calculated as the ratio of each OD to the OD of cells treated with drug alone (set as 1.0). Results are expressed as relative viability±SEM. Asterisk (*) indicates statistical significance when the P-value is lower than 0.05.

Blood Research 2010; 45: 158-163https://doi.org/10.5045/kjh.2010.45.3.158

Fig 3.

Download
Figure 3.

CoCl2 decreases the apoptotic rate of HL-60 cells through the HSP70/Bax pathway. (A) HL-60 or K562 cells were cultured for 24 hrs in the presence or absence of CoCl2. Expression levels of HSP90, HSP70, and Bax were analyzed by western blotting. An α-tubulin antibody was used as an internal control. (B) HL-60 cells were cultured with indicated dose of CoCl2 for 24 hrs. The expression levels of Bax, Bcl-2, ERK, phospho-ERK, HSP70, HSP90, p38, and phospho-p38 were analyzed by western blotting. (C) HL-60 cells were cultured with or without CoCl2 in the presence of ATO for 24 hrs. The amount of cleaved caspase-3 was assessed by flow cytometry. (D) HL-60 cells were cultured with or without ATO in the presence or absence of CoCl2 for 24 hrs. Cells were stained with annexin V/PI and then analyzed by flow cytometry.

Blood Research 2010; 45: 158-163https://doi.org/10.5045/kjh.2010.45.3.158

Fig 4.

Download
Figure 4.

The expression of HIF-1α increases the resistance of HL-60 cells to ATO. (A) HL-60 cells were cultured in the presence of the indicated doses of CoCl2 for 24 hrs. Expression of HIF-1α was then analyzed by western blotting. A β-actin antibody was used as an internal control. (B) HL-60 cells were cultured in the presence or absence of CdCl2 and/or CoCl2 for 12 hrs and with ATO for additional 48 hrs. Cell viability was analyzed by the MTT assay. The relative viable cell number was calculated as the ratio of each OD to the control OD. Results are expressed as relative viability±SEM. Two asterisks (*) represents statistical significance when the P-value is lower than 0.01.

Blood Research 2010; 45: 158-163https://doi.org/10.5045/kjh.2010.45.3.158

References

  1. Zhang, TC, Cao, EH, Li, JF, Ma, W, Qin, JF. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer, 1999;35;1258-1263.
    Pubmed
  2. Park, JW, Choi, YJ, Jang, MA, et al. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun, 2001;286;726-734.
    Pubmed
  3. Uslu, R, Sanli, UA, Sezgin, C, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res, 2000;6;4957-4964.
    Pubmed
  4. Shen, ZY, Shen, J, Cai, WJ, Hong, C, Zheng, MH. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med, 2000;5;155-158.
    Pubmed
  5. Maeda, H, Hori, S, Nishitoh, H, et al. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res, 2001;61;5432-5440.
    Pubmed
  6. Semenza, GL. HIF-1 and human disease: one highly involved factor. Genes Dev, 2000;14;1983-1991.
    Pubmed
  7. Maxwell, PH, Dachs, GU, Gleadle, JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA, 1997;94;8104-8109.
    Pubmed
  8. Dachs, GU, Patterson, AV, Firth, JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med, 1997;3;515-520.
    Pubmed
  9. Semenza, GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med, 2002;8;S62-S67.
    Pubmed
  10. Semenza, GL. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med, 2003;54;17-28.
    Pubmed
  11. Yuan, Y, Hilliard, G, Ferguson, T, Millhorn, DE. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem, 2003;278;15911-15916.
    Pubmed
  12. Jin, L, Hope, KJ, Zhai, Q, Smadja-Joffe, F, Dick, JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med, 2006;12;1167-1174.
    Pubmed
  13. Matsunaga, T, Takemoto, N, Sato, T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med, 2003;9;1158-1165.
    Pubmed
  14. Saitoh, Y, Ouchida, R, Miwa, N. Bcl-2 prevents hypoxia/reoxygenation-induced cell death through suppressed generation of reactive oxygen species and upregulation of Bcl-2 proteins. J Cell Biochem, 2003;90;914-924.
    Pubmed
  15. Santore, MT, McClintock, DS, Lee, VY, Budinger, GR, Chandel, NS. Anoxia-induced apoptosis occurs through a mitochondria-dependent pathway in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol, 2002;282;L727-L734.
    Pubmed
  16. Hussein, D, Estlin, EJ, Dive, C, Makin, GW. Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther, 2006;5;2241-2250.
    Pubmed
  17. Song, X, Liu, X, Chi, W, et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol, 2006;58;776-784.
    Pubmed
  18. Walmsley, SR, Print, C, Farahi, N, et al. Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med, 2005;201;105-115.
    Pubmed
  19. Li, Q, Sato, EF, Zhu, X, Inoue, M. A simultaneous release of SOD1 with cytochrome c regulates mitochondria-dependent apoptosis. Mol Cell Biochem, 2009;322;151-159.
    Pubmed
  20. Khalil, S, Luciano, J, Chen, W, Liu, AY. Dynamic regulation and involvement of the heat shock transcriptional response in arsenic carcinogenesis. J Cell Physiol, 2006;207;562-569.
    Pubmed
  21. Ramos, AM, Aller, P. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines. Biochem Pharmacol, 2008;75;1912-1923.
    Pubmed
  22. Chun, YS, Choi, E, Kim, GT, et al. Cadmium blocks hypoxia-inducible factor (HIF)-1-mediated response to hypoxia by stimulating the proteasome-dependent degradation of HIF-1alpha. Eur J Biochem, 2000;267;4198-4204.
    Pubmed
  23. Seo, YJ, Koh, SH, Kang, HJ, Shin, HY, Jeong, G, Ahn, HS. Hypoxia inhibits the SDF-1-dependent migration of human leukemic cell line HL-60 via blocking of Akt activation. Biochem Biophys Res Commun, 2007;364;388-394.
    Pubmed
  24. Nagata, S. Apoptotic DNA fragmentation. Exp Cell Res, 2000;256;12-18.
    Pubmed
  25. Takahashi, Y, Karbowski, M, Yamaguchi, H, et al. Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. Mol Cell Biol, 2005;25;9369-9382.
    Pubmed
  26. Platanias, LC. Map kinase signaling pathways and hematologic malignancies. Blood, 2003;101;4667-4679.
    Pubmed
  27. Bendall, LJ, Makrynikola, V, Hutchinson, A, Bianchi, AC, Bradstock, KF, Gottlieb, DJ. Stem cell factor enhances the adhesion of AML cells to fibronectin and augments fibronectin-mediated anti-apoptotic and proliferative signals. Leukemia, 1998;12;1375-1382.
    Pubmed
Blood Res
Volume 59 2024
Current Issue Archives

Stats or Metrics

Share this article on

  • line

Related articles in BR

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download